Results 81 to 90 of about 9,643 (207)
International Journal of Dermatology, EarlyView.A bicentric retrospective real‐world study (N = 616) comparing IL‐23 inhibitors (guselkumab, risankizumab, tildrakizumab) with adalimumab biosimilars in moderate‐to‐severe plaque psoriasis. It presents PASI90 response at Weeks 16 and 52, NNT, and cost‐effectiveness (incremental cost per responder, CE plane, CEAC/CEAF).
Gennaro Marco Falco +13 more
wiley +1 more source
PLoS ONEBackgroundBiosimilars have the potential to save a significant amount of money in cancer treatment costs. However, barriers exist in the adoption of biosimilar products.
Hisashi Itoshima +5 more
doaj +1 more source
Denosumab discontinuation and fracture risk: getting the balance right
Internal Medicine Journal, EarlyView.Abstract Denosumab is a highly effective therapy for osteoporosis. Since its approval by the Therapeutic Goods Administration (TGA) in 2010, use of denosumab has surged across Australia, delivering substantial fracture‐prevention benefits to tens of thousands of patients. However, stopping denosumab may lead to acute loss of bone with an increased risk
Albert S. Kim, Christian M. Girgis
wiley +1 more source
Proteomic analysis in hidradenitis suppurativa reveals systemic inflammation in all disease stages
Journal of the European Academy of Dermatology and Venereology, EarlyView.Proteomic profiling reveals systemic inflammation in patients with hidradenitis suppurativa, even in early disease. Distinct mediators (e.g. TGF‐α, OSM, HGF) are elevated early, whereas others correlate with clinical severity (e.g. IL‐6, VEGF‐A, IL‐17A) or disease duration (e.g.
Lotta Sandelin Francke +5 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 684-691, September 2026.Biologic therapies are a major and growing driver of pharmaceutical expenditure globally, with tumor necrosis factor (TNF) inhibitors among the most widely used and costly biologics. In Australia, these therapies are funded through the Pharmaceutical Benefits Scheme (PBS), where biosimilars offer lower cost alternatives; however, the long‐term public ...
Chin Hang Yiu +4 more
wiley +1 more source
The Laryngoscope, Volume 136, Issue S4, Page S7-S17, September 2026.ABSTRACT Objective With regulatory approval of HPV‐specific immunotherapy for recurrent respiratory papillomatosis (RRP) and growing experience with systemic bevacizumab, a management algorithm incorporating these medical treatments is warranted. Data Sources and Methods RRP Foundation (RRPF) Key Opinion Leaders offer a proposed management algorithm ...
Simon R. Best +17 more
wiley +1 more source
Inflammatory Bowel Disease: Mechanisms and Therapeutic Advances
MedComm, Volume 7, Issue 9, September 2026.Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, is a rising, multifactorial chronic disorder driven by dysregulated mucosal immunity in genetically susceptible individuals and influenced by environmental and microbial factors.
Andrea Papait +5 more
wiley +1 more source
ClinicoEconomics and Outcomes ResearchGrace E Fox,1 Mark Bernauer,1 Jennifer M Stephens,1 Bianca Jackson,1 Joshua A Roth,2 Ahmed Shelbaya2,3 1Strategic Market Access, OPEN Health, Bethesda, MD, USA; 2Global Access and Value, Pfizer Inc., New York, NY, USA; 3Department of Epidemiology ...
Fox GE +5 more
doaj
Global Health Research and PolicyBackground The Chinese biosimilar industry has demonstrated rapid growth in recent years. Limited evidence is available about biosimilar uptake at the national level.
Qiyou Wu +4 more
doaj +1 more source